Last checked at 18 Aug 2011 13:49
For immediate release | 18 August 2011 |
Futura Medical plc
("Futura" or "the Company")
Directors' Long Term Incentive Scheme
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that the issue of the CE mark for CSD500 on 8 August 2011 will trigger an award of 550,000 Phantom Option Units in accordance with the Company's Long Term Incentive Scheme ("LTIS") and as previously disclosed in the Company's annual report.
Further details of this award will be given in due course and, in accordance with the LTIS, will be based on the Company's closing share price on the 8 August 2011. The determination will take place as soon as practicable after the release of the Company's interim results for the six months ended 30 June 2011 to be reported on 27 September 2011 and the consequent expiry of the current close period. A further announcement will be made in due course.
Details of the LTIS are set out on the Company's website under Governance.
For any further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive
| Tel: +44 (0)1483 685 670 |
mail to: james.barder@futuramedical.com | www.futuramedical.com |
|
|
Nomura Code Securities Limited |
|
Phil Walker / Giles Balleny | Tel:+44 (0)20 7776 1200 |
|
|
For media enquiries please contact: |
|
|
|
Buchanan Communications |
|
Mark Court | Tel: +44 (0)20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com